Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict and treat cancer wasting better? a new study investigates

NCT ID NCT07776353

Knowledge-focused Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study is looking at why some people with advanced cancer lose weight and muscle, a condition called cachexia. Researchers will follow 800 patients with advanced lung, pancreatic, or colorectal cancer to see if there are distinct subtypes of cachexia based on symptoms, biomarkers, and body composition. The goal is to improve how cachexia is diagnosed and treated, potentially leading to more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could lead to better ways to diagnose and treat cancer-related wasting, potentially improving quality of life and survival for advanced cancer patients.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all cancer types or patients, and identifying distinct subtypes does not guarantee that targeted treatments will be effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing treatment for non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, or colorectal cancer.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a primary diagnosis of unresectable or Stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer (CRC). Note: Patients do not need to have cachexia to be eligible * Plan to start first line systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy) in the next 6 weeks or has started first-line systemic therapy in the previous 6 weeks. Note: Patients who received systemic anti-cancer therapy previously as part of adjuvant or neoadjuvant therapy and have since recurred are still eligible if such treatment was longer than 6 months prior to enrollment. * Have an an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. * Be able to understand, speak and read English. * Be 18 years or older Exclusion Criteria: * Have contraindications to physical function assessments (30-second bicep curl, Timed-Up-And-Go test, or 30-Second Sit to Stand test) per the treating provider or their designee. * Have any planned major surgeries within the next 3 months after enrollment to the best knowledge of the investigator/treating provider or their designee. * Have received chemotherapy or surgery for separate primary cancer within the past 3 years other than non-melanoma skin cancer. * Be pregnant or within 6 months postpartum.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced colorectal carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic disorder colorectal cancer colorectal carcinoma colorectal neoplasm Digestive System Diseases digestive system disorder digestive system neoplasm Digestive System Neoplasms disease endocrine system disorder intestinal cancer intestinal disorder lung cancer lung disorder lung neoplasm malignant endocrine neoplasm malignant pancreatic neoplasm neoplasm Neoplasms by Site non-small cell lung carcinoma pancreas disorder pancreatic adenocarcinoma pancreatic neoplasm rectal disorder respiratory system disorder respiratory tract neoplasm Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced colorectal carcinoma Advanced lung non-small cell carcinoma Advanced pancreatic adenocarcinoma Stage IV colorectal cancer ajcc V8 Stage IV lung cancer ajcc V8 Stage IV pancreatic cancer ajcc V8 Unresectable colorectal carcinoma Unresectable lung non-small cell carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kaiser Permanente Northern California

    RECRUITING

    Pleasanton, California, 94588, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.